Anirban Maitra (@Aiims1742) ranks #34 among US lung cancer KOLs, #4 among US gi cancer KOLs on X in 2026, by engagement from fellow physicians. 134 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: RASolute 302. CMS Open Payments lists $247 in 2025 general payments.
At a Glance
- 2 posts naming a trial in 2026
- 1 trials discussed by name
- Lung Cancer: US #34 · 6 physicians engaged
- GI Cancer: US #4, Global #7 · 134 physicians engaged
- Leading physician voice: #2 of 73 physicians on RASolute 302
- CMS Open Payments lists $247 in 2025 general payments.
This Month
What Anirban Maitra has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Who Amplifies Anirban Maitra
Physicians who reposted Anirban Maitra’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #34 | — | 6 | 6 | Full ranking |
| GI Cancer | #4 | #7 | 134 | 192 |
What Colleagues Are Saying About Anirban Maitra
2026 posts by fellow physicians that mention @Aiims1742, quoted word for word.
Super excited! Daraxonrasib from @RevMedicines approved by FDA! We were very fortunate with EAP @Perlmutter_CC and team led by @md_oberstein @Aiims1742 @DrMhidalgo. Incredible EAP efforts and now ready to move into practice!
Trials Anirban Maitra Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| RASolute 302 | 2 | #2 of 73 | Apr 21, 2026 |
Anirban Maitra on RASolute 302
Daraxonrasib phase 3 (RASolute 302) data to be presented at #ASCO26 plenary session on May 31st. https://t.co/H7XyO8quIV
🚨🚨🚨 RASOLUTE-302 Ph3 is POSITIVE "Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW! AMAZING news for patients with #PancreaticCancer The RAS Revolution is ON!! https://t.co/I59NNWRB1O
Anirban Maitra’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
From @RevMedicines data on Zoldonrasib plus Daraxonrasib in 2nd & 3rd line metastatic #PancreaticCancer - presented at #ESMOGI26 Small numbers but even a few years back, who would have imagined survival curves like this in 2nd & 3rd line metastatic PANCREATIC cancer? Amazing! https://t.co/JF79pJHH2A
Headed to #AACR26, the same week we had practice changing clinical trial data in #PancreaticCancer with a KRAS inhibitor. Reminded of this critique that @Pasca_Lab received on her grant in 2013 - "There are not, and will never be, KRAS inhibitors". Keep calm & science on! https://t.co/cPr4Nflyd6
Amazing news today, culmination of years of research & clinical trials in #PancreaticCancer. The @RevMedicines approval for Rasonque (Daraxonrasib) will open many doors, including other inhibitors in this space & combinations. @OncoAlert @KRASKickers https://t.co/07rvyKVQpy
Great presentation from the “Queen of KRAS inhibitors” Mallika Singh @RevMedicines at #AACR26. Their portfolio of assets allows targeting of RAS in allele agnostic & allele specific manner using the tri-complex platform. The ongoing studies are all about “doubling down on RAS”. https://t.co/NIsyUVerJU
#AACR26 late breaking abstract on early data from 1st line Daraxonrasib monotherapy in #PancreaticCancer >90% disease control rate https://t.co/YIykE0HpCS @EileenMOReilly @GarridoLagunaMD @DrShubhamPant @RevMedicines https://t.co/1gwEhj6Xsy
Industry Payments
CMS Open Payments · 2025 general payments
$247 across 3 payments